# Isomorphic Labs Closes $2.1 Billion Series B, Second-Largest in Sector History

> financing · REPORTED · 2026-05-01

Isomorphic Labs, the AI drug discovery spinout from DeepMind, closed a $2.1 billion Series B round in May 2026, described as the second-largest financing in the life-science sector's history, fueling its AI-driven small-molecule drug design platform.

About Isomorphic Labs: Isomorphic Labs is an AI-first drug discovery company spun out of Alphabet's DeepMind, applying machine learning and structural biology models including AlphaFold to design novel small-molecule therapeutics across multiple disease areas.

- Company: Isomorphic Labs
- Sector: biotech
- Primary source: https://www.biospace.com/business/q2-earnings-arrive-as-pharma-picks-up-steam-buoyed-by-dealmaking-policy-tailwinds

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.